Veeda Oncology, the US-based specialist research services subsidiary launched in April 2008 by Anglo-Indian contract research organisation (CRO) Veeda Clinical Research, says it has been awarded US$3 million worth of new clinical research programmes over the last 30 days.

The programmes will be carried out at Veeda Oncology sites in North America. Supplied services will include site feasibility, site management, project management, quality assurance, scientific review and medical support. According to Matt Bowman, president and chief executive officer of Veeda Oncology, the new business awards are “directly related to our ability to provide qualified oncology sites with the capability to begin accruing patients very rapidly”.

Veeda Oncology is a full-service oncology CRO with operations in India, Eastern Europe, Western Europe and the US. Last May it completed the acquisition of Biologie et Industrie, an oncology CRO based in Paris, France. Veeda Oncology subsequently gained access to 50 trial sites in the US by snapping up International Oncology Network Clinical Research, a diversified physician services network claiming to represent around half of the private-practice oncologists in the US, last July.